If you have not done so already, we invite you to subscribe to Essential Action's Global Access to Medicines Bulletin (see below for the latest issue, or go to www.essentialaction.org/access/ to download the RTF version posted on our website).
The second issue discusses the pharmaceutical industry's most frequent justification for high drug prices in the developing world: the cost of research and development (R&D) for new treatments. Our conclusion? That Pharma's R&D cost estimates are often overblown, and that generic competition in the developing world will not significantly undermine industry's ability to develop new drugs.
To subscribe to the bulletin, click here
http://salsa.democracyinaction.org/o/1678/t/5144/signUp.jsp?key=2959
We apologize if you have already received this message or have already subscribed to the bulletin. We are sending the first three issues of the bulletin to personal contacts as well as those who have subscribed, and some duplication may occur.
Best,
Sarah Rimmington and Robert Weissman
Essential Action
mailto:rob@essential.org